Endospan Completes Acquisition by Artivion, Inc. After FDA Approval of the NEXUS® Aortic Arch System
Endospan has announced the completion of its acquisition by Artivion in a deal that significantly strengthens Artivion’s position in the global aortic repair market and expands access to advanced endovascular technologies for the treatment of complex aortic arch diseases. The acquisition follows a major regulatory milestone for Endospan earlier this year, when the company received U.S. Food and Drug Administration approval for its NEXUS® Aortic Arch System, a first-in-class off-the-shelf endovascular device designed specifically for aortic arch pathologies.
The transaction represents an important strategic development in the rapidly evolving field of aortic disease treatment, where physicians increasingly seek minimally invasive alternatives to highly complex open surgical procedures. Under the terms of the agreement, Artivion will acquire Endospan for an upfront purchase price of $175 million, adjusted for previously provided loans, along with the possibility of up to an additional $200 million in milestone-based consideration tied to the future U.S. commercial performance of the NEXUS platform during the next two years.
The acquisition positions Artivion as one of the few companies globally capable of offering a broad and integrated portfolio of technologies addressing multiple approaches to aortic arch repair, including open surgery, hybrid interventions, and fully endovascular procedures. Industry observers view the transaction as a major step toward consolidating advanced aortic treatment capabilities under a single commercial and clinical platform.
The timing of the acquisition is particularly significant because it comes shortly after the FDA granted Premarket Approval for the NEXUS Aortic Arch System in April 2026. The approval marked a historic achievement for Endospan, as NEXUS became the first commercially available off-the-shelf endovascular system specifically designed to treat aortic arch disease, including chronic aortic dissections, in patients considered high risk for traditional open surgical repair.
Aortic arch disease remains one of the most technically challenging areas in cardiovascular medicine. The aortic arch is anatomically complex because it contains critical blood vessels supplying the brain and upper body. Conventional open surgery for these conditions often requires cardiopulmonary bypass, circulatory arrest, and extensive operative reconstruction, procedures that can carry substantial risks, particularly among elderly or medically fragile patients.
Endovascular approaches aim to reduce those risks by allowing physicians to treat diseased sections of the aorta through catheter-based procedures rather than large open surgeries. However, until recently, most endovascular technologies available for the aortic arch required highly customized device manufacturing or complex physician-modified solutions, limiting broader accessibility and delaying treatment timelines.
The NEXUS system was developed specifically to address these limitations. As an off-the-shelf solution, the platform is designed to provide physicians with a readily available treatment option that can be deployed more rapidly in appropriate patients while maintaining compatibility with the challenging anatomy of the ascending aorta and aortic arch.
According to Endospan executives, the FDA approval validated years of engineering and clinical development efforts focused on creating a device capable of addressing diseases that previously had limited minimally invasive treatment options.
Kevin Mayberry, Chief Executive Officer of Endospan, described the FDA approval as a pivotal moment for aortic surgeons and cardiovascular specialists seeking technologies purpose-built for the ascending aorta and aortic arch.
Mayberry stated that the acquisition by Artivion places the NEXUS platform within an organization deeply familiar with the aortic treatment landscape. He emphasized that Artivion’s established expertise across open surgical, endovascular, and hybrid treatment modalities creates an environment where the NEXUS system can become part of a broader multidisciplinary treatment strategy for complex aortic disease.
The transaction also significantly expands Artivion’s already substantial presence within the global aortic repair market. Artivion has long been recognized for its portfolio of cardiovascular surgical technologies, including products used in aortic reconstruction, tissue preservation, and vascular repair. With the addition of Endospan’s technologies, the company now strengthens its ability to offer physicians a comprehensive range of treatment options for diverse patient populations.
One of the most important aspects of the acquisition is the integration of NEXUS into what Artivion describes as a “three-pronged” aortic arch portfolio. The company now combines the NEXUS platform with its existing AMDS and ARCEVO LSA technologies, creating what executives characterize as one of the industry’s most complete collections of aortic arch treatment solutions.
Pat Mackin, Chairman, President, and Chief Executive Officer of Artivion, stated that the acquisition solidifies the company’s leadership position within the specialized aortic arch market segment. According to Mackin, Artivion is now uniquely positioned as the only company globally offering a comprehensive portfolio that spans multiple therapeutic approaches for aortic arch disease.
He also stressed that the NEXUS platform should not be viewed as a single standalone product. Instead, Artivion sees the technology as the foundation for a broader family of next-generation aortic arch devices currently in development.
The acquisition includes access to Endospan’s expanding research and development pipeline, which contains additional technologies aimed at advancing minimally invasive treatment strategies for complex aortic conditions. Artivion believes these future innovations could further strengthen the company’s long-term competitive position in the global aortic repair market.
Beyond the United States, the acquisition further enhances Artivion’s commercial presence in international markets where Endospan technologies are already established. Since 2019, Artivion has served as the exclusive distributor for the NEXUS system throughout Europe, the Middle East, and Africa. This longstanding commercial relationship provided Artivion with significant familiarity regarding the platform’s clinical use, physician adoption patterns, and market potential prior to the acquisition.
The companies also highlighted the importance of Endospan’s broader international product portfolio, which includes a range of technologies tailored for varying anatomical and clinical needs. In Europe, Asia-Pacific, and Latin America, Endospan has developed solutions spanning from standardized off-the-shelf systems to highly customized multi-branch configurations such as NEXUS DUO and NEXUS TRE.
These technologies are intended to provide physicians with greater procedural flexibility when managing complex aortic arch anatomies that may not be adequately addressed using conventional endovascular graft systems. The expanded portfolio also reflects growing demand for personalized and adaptable solutions in cardiovascular interventions.
The acquisition comes at a time when the global market for minimally invasive cardiovascular procedures continues to expand rapidly. Advances in imaging, catheter-based delivery systems, stent graft technologies, and hybrid operating environments have increasingly shifted complex vascular interventions toward endovascular treatment strategies.
Patients considered unsuitable for open surgery because of advanced age, frailty, or coexisting medical conditions are particularly driving demand for less invasive alternatives. Chronic aortic dissections and complex aortic arch aneurysms remain associated with high mortality and morbidity when untreated, creating substantial clinical demand for safer and more accessible intervention options.
Industry analysts believe the FDA approval of the NEXUS system may represent a turning point for endovascular aortic arch repair in the United States. Historically, many aortic arch cases have remained dependent on highly specialized surgical centers capable of performing technically demanding open reconstructions. The availability of an approved off-the-shelf endovascular solution could potentially broaden treatment access and expand procedural adoption among qualified centers.
Artivion’s commercial infrastructure may also accelerate physician education and market penetration for the technology. With established relationships across cardiac and vascular surgery communities worldwide, the company is positioned to support broader clinical training and adoption efforts as the U.S. launch progresses.
While Artivion prepares for the full commercial rollout of the NEXUS platform in the United States, the company appears focused on integrating Endospan’s technologies into a broader strategic vision centered on comprehensive aortic disease management. Executives believe that combining open, hybrid, and endovascular capabilities under a single portfolio may better align with the multidisciplinary nature of modern cardiovascular care.
The acquisition also reflects ongoing consolidation within the medical technology industry, where larger companies increasingly seek innovative platform technologies capable of expanding procedural indications and strengthening long-term market leadership. For Endospan, the transaction provides access to greater commercial resources, operational scale, and global infrastructure that may accelerate adoption of its technologies across international markets.
For Artivion, the acquisition delivers not only an FDA-approved first-in-class product but also an expanding innovation platform that could shape the future direction of minimally invasive aortic arch treatment. As cardiovascular medicine continues moving toward more personalized and less invasive therapeutic approaches, the integration of Endospan’s NEXUS technology may play an important role in redefining how physicians manage some of the most complex diseases affecting the thoracic aorta.
About Endospan
Privately held Endospan, headquartered in Herzliya (Tel Aviv), Israel, is a pioneer in the endovascular repair of aortic arch disease including aneurysms and dissections. Endospan’s NEXUS® Aortic Arch Stent-Graft System was the first endovascular off-the-shelf system with CE Mark to treat an underserved group of patients diagnosed with a dilative lesion in, or near, the aortic arch and ascending expanding minimally invasive endovascular repair in this anatomical region. For additional information about Endospan, visit its website at www.endospan.com.
About Artivion, Inc. Headquartered in suburban Atlanta, Georgia, Artivion, Inc., is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons’ most difficult challenges in treating patients with aortic diseases. Artivion’s four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.
